Your SlideShare is downloading. ×
Mecanismos de resistencia del Streptococcus pneumoniae
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Mecanismos de resistencia del Streptococcus pneumoniae

1,306
views

Published on

Mecanismos de resistencia del Streptococcus pneumoniae

Mecanismos de resistencia del Streptococcus pneumoniae


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,306
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
32
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Review Mechanisms of antibiotic resistance and tolerance in Streptococcus pneumoniae Emmanuelle Charpentiera , Elaine Tuomanenb * a Department of Molecular Pathogenesis, Skirball Institute of Biomolecular Medicine, New York, NY 10016, USA b Department of Infectious Diseases, St Jude Children’s Research Hospital, 332 N. Lauderdale St., Memphis, TN 38105, USA ABSTRACT – Streptococcus pneumoniae is a major pathogen causing potentially life-threatening community-acquired diseases in both the developed and developing world. Since 1967, there has been a dramatic increase in the incidence of penicillin-resistant and multiply antibiotic-resistant pneumococci worldwide. Prevention of access of the antibiotic to the target, inactivation of the antibiotic and alteration of the target are mechanisms that S. pneumoniae has developed to resist antibiotics. Recent studies on antibiotic-tolerant pneumococcal mutants permitted development of a novel model for the control of bacterial cell death. © 2000 Éditions scientifiques et médicales Elsevier SAS Streptococcus pneumoniae / antibiotic resistance / penicillin-binding proteins / antibiotic tolerance / autolysin / signal transduction / cell death 1. Introduction Streptococcus pneumoniae is a Gram-positive patho- gen and is one of the most common causes of community- acquired diseases, such as pneumonia, otitis media, sep- ticemia, bacterial meningitis and others. The morbidity and mortality of infections caused by S. pneumoniae remain high despite appropriate antibiotic therapy. Since 1940, penicillin has been the drug of choice for the treatment of pneumococcal infections. The first clinical isolate resistant to penicillin was described in 1967, where it was recovered from a patient in Papua New Guinea [1]. The tremendous increase in antibiotic usage worldwide has strongly contributed to the emergence of multidrug- resistant pneumococci. The sentinel event in the epidemi- ology of antibiotic-resistant pneumococci was the out- break in 1977 in South Africa of pneumococcal diseases caused by multidrug-resistant strains [2]. In addition to being highly resistant to penicillin (a 1 000-fold increase of the MIC), these strains were found to be resistant to erythromycin, clindamycin, tetracycline and chloram- phenicol. In this article, we review the different mecha- nisms that have been employed by S. pneumoniae to develop resistance against penicillins, cephalosporins, fluoroquinolones, macrolides, tetracycline, chlorampheni- col and trimethoprim-sulfamethoxazole (table I). Recent discoveries about pneumococcal signal transduction path- ways involved in bacterial cell death and their role in antibiotic tolerance will be discussed. 2. Mechanisms of antibiotic resistance in S. pneumoniae 2.1. β-lactams The mechanism of action of β-lactams is based on the binding of the antibiotic to cell wall synthesizing enzymes, the penicillin-binding proteins (PBPs), thereby interfering with the biosynthesis and remodeling of the bacterial peptidoglycan. Binding of β-lactams to PBPs leads to a covalently deacylated complex removing the PBPs from the metabolically active pool [3]. The mechanism of penicillin resistance in clinical iso- lates of S. pneumoniae involves the alteration of PBPs so as to reduce their affinity for the antibiotic molecule (table I). Mutations leading to resistance to penicillin are usually present in the transpeptidase-penicillin-binding domain [4]. To lead to reduced affinity to penicillin, a PBP has to acquire multiple mutations so that high-level resistance is reached by the acquisition of more than one low-affinity PBP variant. In pneumococcus, five PBPs of high molecu- lar weight (PBPs 1a, 1b, 2x, 2a and 2b) and one PBP of low molecular weight have been described [5]. Alterations in PBP2x and PBP2b confer low-level resistance and are the prerequisite for high-level resistance mediated by muta- tions in other PBPs, like PBP1a [4, 6]. Resistance in many pneumococcal clinical isolates is due to changes in only these three PBPs. In addition to its central role in confer- ring high-level resistance, PBP2b seems to be related to the bacteriolytic activity of penicillins [6]. The observation that third generation cephalosporins, another group of β-lactam antibiotics, induce less lysis in pneumococci is * Correspondence and reprints. E-mail address: elaine.tuomanen@stjude.org (E. Tuomanen). Microbes and Infection, 2, 2000, 1855−1864 © 2000 Éditions scientifiques et médicales Elsevier SAS. All rights reserved S1286457900013459/REV Microbes and Infection 2000, 1855-0 1855
  • 2. based on the fact that they do not interact with PBP2b. Pneumococci more resistant to the extended-spectrum cephalosporins than to penicillin G have been described; this pattern of resistance appears to be due to unique alterations in PBPs such as PBP2x and PBP1a (table I) [7]. In pneumococcus, the genes that encode the altered PBPs are called mosaic genes. This feature refers to the existence of long, contiguous nucleotide sequences within the PBP genes, which appear to be divergent, i.e. non- pneumococcal origin [8]. Mosaic genes have emerged in naturally transformable organisms like neisseriae and strep- tococci most likely due to the ability to exchange genetic material via homologous recombination of distinct alleles [5]. The presence of extended DNA sequences in the PBP genes modifies not only the active site of these proteins but perhaps also some secondary domains involved in the recognition of the muropeptide structure that these bacte- ria use for building their particular clone-specific pepti- doglycan [4, 9]. The origin of these mosaic blocks seems to be traceable to other commensal species of strepto- cocci, since closely related or even identical blocks of sequences have been identified in resistant strains of Strep- tococcus sanguis, Streptococcus mitis and Streptococcus oralis [10–12]. The existence of identical PBP genes in genetically distinct clones of penicillin-resistant S. pneu- moniae demonstrates the horizontal spread of resistance determinants within one species. A model for the origin of penicillin resistance and the mechanism by which resis- tance levels increase has been proposed [13, 14]. Acqui- sition of mosaic genes may occur in a stepwise manner. Incorporation of one of such altered low-affinity PBP gene marks the beginning of a resistant clone, which then expands through cell division until one of this lineage engages in a second recombinational event that results in the modification of another of the high-molecular-weight PBP genes in the recipient pneumococcus. The progeny of such a cell (which now has an increased MIC to penicillin) may undergo further recombination events, each of which increases the resistance level further [14]. Two alternative mechanisms of β-lactam resistance have recently been described in vitro in pneumococcus. Both mechanisms would most likely be involved in the biosyn- thesis of cell wall components acting upstream of the biosynthetic function of PBPs [4]. The first mechanism involves a putative glycosyltransferase, CpoA, which seems to act as the primary determinant. It was found in a laboratory mutant obtained upon selection with piperacil- lin, a highly lytic β-lactam that has high affinity to all pneumococcal PBPs [15]. CpoA could be involved in teichoic acid biosynthesis by transferring carbohydrates to the lipid intermediate [4]. The second mechanism refers to a putative histidine kinase encoded by the gene ciaH and identified in a laboratory mutant resistant to cefotaxime, a third generation cephalosporin that does not induce much lysis [16]. It was proposed that the cia system might be involved in sensing and counteracting cell wall damage induced upon β-lactam treatment. No clinical correlate implicating these alternative pathways of penicillin resis- tance has been identified yet. No mechanism of penicillin resistance involving β-lactamase has been reported thus far in S. pneumoniae. 2.2. Fluoroquinolones Quinolones such as the new fluoroquinolones, trova- floxacin and moxifloxacin, appeared as alternative thera- peutic agents for the treatment of penicillin-resistant pneu- mococcal infections. Fluoroquinolones principally target the type II topoisomerase A2B2 complex, also called DNA gyrase, that catalyzes DNA supercoiling during replica- tion, and the topoisomerase IV complex C2E2 that is essen- tial for chromosome segregation [17]. In clinical isolates of pneumococci, fluoroquinolone resistance is mediated by target modifications that involve mutations in the gyrase genes, gyrA and gyrB, and in the topoisomerase IV genes, parC and parE (table I). However, in vitro studies have indicated that some strains may use an efflux mechanism resulting in reduced intracellular accumulation of the antibiotic [18, 19]. The presence of mutations in gyrA and parC, the order of appearance of the mutations and the type of fluoroquinolone that induce the mutations constitute factors in the development of resis- tance to fluoroquinolones. Ciprofloxacin resistance in pneumococcus results from initial and necessary parC mutations leading to low level of resistance, and subse- quent gyrA mutations lead to higher levels of resistance [20, 21]. The mutations in parC that have been described thus far in clinical isolates and laboratory mutants involve substitutions of Ser-79 to Tyr/Phe or Asp-83 to Gly/Ala, and the mutations in gyrA include substitutions of Ser-83 to Tyr/Phe or Glu-88 to Gln/Lys [20–23]. In contrast to cipro- floxacin resistance, sparfloxacin resistance results initially from mutations in gyrA and subsequently, additional muta Table I. Mechanisms of antibiotic resistance in S. pneumoniae. Antibiotic family Antibiotic agent Target Resistance mechanism β-lactams penicillin PBPa altered target cephalosporin PBP altered target Fluoroquinolones ciprofloxacin sparfloxacin DNA gyrase and topoisomerase IV altered target, efflux DNA gyrase and topoisomerase IV altered target, efflux Macrolides erythromycin 23S ribosomal RNA altered target, efflux Chloramphenicol chloramphenicol 50S ribosomal subunit antibiotic enzymatic modification Tetracycline tetracycline 30S ribosomal subunit altered target Diaminopyrimidine trimethoprim DHFRa altered target Sulphonamide sulfamethoxazole DHPSa altered target a PBP, penicillin-binding protein; DHFR, dihydrofolate reductase; DHPS, dihydropteroate reductase. Review Charpentier and Tuomanen 1856 Microbes and Infection 2000, 1855-0
  • 3. tions in parC. A mutation in gyrA resulting in substitution of Ser-83 to Tyr/Phe and mutations in parC leading to changes of Ser-79 to Tyr and Asp-83 to Asn were detected in clinical isolates and laboratory mutants resistant to sparfloxacin [23, 24]. High level of resistance to clina- floxacin in laboratory mutants of S. pneumoniae requires stepwise and multiple mutations in gyrA and parC [25]. By aligning the DNA sequences of gyrA and parC, it is obvi- ous that the mutation hotspots in gyrA (Ser-83 and Glu-88) correspond to those in parC (Ser-79 and Asp-83). It was thus proposed that the interactions of fluoroquinolones with GyrA would be similar to those with ParC. The gyrB and parE genes share significant homology. A mutation in parE leading to a single amino acid substitution of Asp-435 to Asn was described in pneumococcal clinical and labo- ratory mutants conferring low-level resistance to fluoro- quinolone, whereas sequential acquisitions of mutations in parE and gyrA are required to reach higher levels of resistance [26, 27]. A mutation in gyrB changing Ser-127 to Leu that resulted in novobiocin resistance was reported in laboratory mutants [22]. No mutation in gyrB conferring quinolone resistance has yet been reported in pneumo- coccal clinical isolates. Antibiotic efflux was recently suggested to be a likely relevant mechanism in clinical isolates of S. pneumoniae resistant to fluoroquinolones (table I) [28, 29]. An active efflux mechanism of fluoroquinolones similar to that con- ferred by NorA, a membrane-associated active efflux pump in Staphylococus aureus, was identified in a pneumococ- cal laboratory mutant [30]. An efflux protein, PmrA, which confers resistance to norfloxacin was recently character- ized in vitro in S. pneumoniae [31]. 2.3. Macrolide-lincosamide-streptogramins (MLS) Although MLS antibiotics are chemically distinct, they competitively interact when binding to the ribosomal 50S subunit, where only one molecule is able to bind [32]. Two mechanisms of resistance to MLS in clinical iso- lates of pneumococci have already been reported: modi- fication of the target that results in co-resistance to MLS and efflux of the antibiotic that mediates resistance to 14-membered and 15-membered macrolides only result- ing in a so-called M phenotype (table I) [18, 33]. Co-resistance to MLS involves the gene erm encoding an S-adenosylmethionine-dependent methylase that methy- lates an adenine residue in the peptidyl transferase domain of the 23S rRNA. The rRNA methylation leads most likely to a conformational change in the ribosome, thus reducing the affinity of MLS antibiotics for the rRNA [34]. Descrip- tion of the gene ermAM carried on the conjugative trans- poson Tn1545 or a transposon similar to Tn917 was reported in pneumococcal clinical isolates [35]. The M resistance phenotype is conferred by a mechanism of efflux of the antibiotic from the cell [36]. The gene mefE encodes a transmembrane hydrophobic protein that plays a role of efflux pump by most likely using the proton motive force. This mechanism appears to be rapidly emerg- ing as the predominant mechanism of resistance to eryth- romycin in clinical isolates of pneumococci isolated in many countries [37]. 2.4. Chloramphenicol Chloramphenicol inhibits bacterial protein synthesis by targeting the peptidyl transferase during translation [38]. In pneumococci, resistance to chloramphenicol is due to the production of the chloramphenicol acetyltrans- ferase enzyme catalyzing the conversion of chlorampheni- col to derivatives, which are unable to bind the ribosomal 50S subunit and therefore are no longer capable of inac- tivating the peptidyltransferase (table I) [39]. Pneumococ- cal clinical isolates harboring the gene cat carried on the conjugative transposon Tn5253, a composite transposon consisting of the tetracycline resistance transposon Tn5251 and Tn5252 were identified [40]. Chloramphenicol- resistant pneumococcal clinical strains containing sequences homologous or identical to the cat gene encoded by the plasmid pC194 from S. aureus have also been reported [41, 42]. 2.5. Tetracycline Tetracyclines cause bacteriostasis by binding to either the acceptor site (A-site) or the peptidyl-donor site (P-site) of the 30S subunit of the bacterial ribosome, thus prevent- ing binding of the aminoacyl-tRNA to the A-site [38]. Ribosomal protection mediated by the genes tet(M) and tet(O) is the only resistance mechanism that has been described thus far in pneumococcus (table I) [43, 44]. Pneumococcal resistant strains harboring tet(M) located on the transposons Tn1545 and Tn5251 were isolated [40, 45]. The precise mechanism by which the proteins Tet(M) and Tet(O) protect the ribosome from the action of tetra- cycline is still unclear. It was suggested that Tet(M) would promote the release of tetracycline from the ribosome in a mechanism involving GTP as an energy source and that it could function either as a tetracycline-resistant analog of this elongation factor(s) or by modifying the target sites on the ribosome in a catalytic fashion [46, 47]. It was also considered that Tet(M) might be involved in modifying the tRNA in such a way that its binding to the ribosome is not affected by the presence of tetracycline [48]. 2.6. Trimethoprim-sulfamethoxazole The combination of trimethoprim with sulfamethox- azole (cotrimoxazole) has been used extensively for the treatment of lower respiratory tract infections in develop- ing countries because of its attractive cost and effective- ness [49]. Trimethoprim and sulfamethoxazole interfere with the biosynthesis of folic acid [50]. Trimethoprim selectively inhibits bacterial dihydrofolate reductase (DHFR) thus preventing the reduction of dihydrofolate to tetrahydrofolate. Sulfamethoxazole competes with para- aminobenzoate for dihydropteroate synthetase (DHPS), preventing the production of 7,8-dihydropteroate and thus stopping DNA synthesis [50]. Trimethoprim resistance in clinical isolates of S. pneu- moniae results from a single amino acid substitution (Ile- 100 to Leu) in the chromosomal-encoded DHFR (table I). It was suggested that this amino acid change would prob- ably disrupt the hydrogen bonding of the DHFR to the 4-amino group of trimethoprim thus altering the DHFR function [51]. The nature of the mechanisms resulting in high levels of trimethoprim resistance in pneumococcus Antibiotic resistance and tolerance in S. pneumoniae Review Microbes and Infection 2000, 1855-0 1857
  • 4. remains unknown. Resistance to sulfamethoxazole in pneumococcal clinical isolates is due to altered chromosomal-encoded DHPS (table I) [49]. Duplication of either three or six bases resulting in the repetition of one or two amino acids in the region from Arg-58 to Tyr-63 of the chromosomal-encoded DHPS was identified in a resis- tant isolate. In a laboratory mutant, a duplication of amino acids 66 and 67 in the chromosomal-encoded DHPS was also described [52]. More recently, a duplication of Ser- 61, a duplication of Arg-58 and Pro-59 and an insertion of an arginine residue between Gly-60 and Ser-61 in DHPS were detected in South African clinical strains of S. pneu- moniae resistant to trimethoprim-sulfamethoxazole [53]. 2.7. Glycopeptides The glycopeptide antibiotics, vancomycin and teico- planin, exert their antimicrobial action by preventing both the transglycosylation and transpeptidation reactions that mediate the formation of mature cell wall [54]. They have been considered as the drugs of last resort for infections due to penicillin-resistant pneumococci. No resistance to glycopeptides in S. pneumoniae has been thus far identi- fied. Nevertheless, of great concern is the possibility that the vancomycin-resistance genes found in enterococci may be transferred to pneumococci. These enterococcal genes encoding modified cell wall precursors with decreased affinity for vancomycin could confer high levels of resistance and are carried by transmissible elements [55]. 3. Epidemiology of antibiotic resistance in S. pneumoniae 3.1. β-lactams It was not until the 1960s that reports of strains of pneumococci with intermediate levels of penicillin resis- tance (MICs, 0.1–0.6 µg/mL) began to appear. The first penicillin-resistant clinical isolate of S. pneumoniae (MIC, 0.5 µg/mL) was described in 1967 in Papua New Guinea [1, 56]. Between 1967 and 1977, sporadic reports of penicillin- resistant clinical isolates were published from various parts of the world. The first dramatic report was the out- break of epidemic pneumococcal disease caused by multidrug-resistant strains in South Africa in 1977. In addition to exhibiting greatly increased MICs of penicillin of 4 to up to 8 µg/mL, these isolates were also resistant to chloramphenicol or to tetracycline, erythromycin, clinda- mycin and chloramphenicol [57, 58]. Since then, penicillin-resistant clinical isolates of pneu- mococci have spread increasingly worldwide [2, 59]. By the early 1980s, geographic areas where more than 10% of isolates were found to be penicillin-resistant included Israel, France, Hungary, Poland, Spain, South Africa, New Guinea and the United States from New Mexico to Alaska. During the 1980s in the United States, several large multicenter studies showed that the prevalence of S. pneu- moniae with decreased susceptibility to penicillin was about 4–5% and bacteria with higher level resistance (≥ 4 µg/mL) were extremely rare [60, 61]. During the same period in a number of countries including South Korea, Hungary and Spain, dramatic increases in penicillin resis- tance were reported. In 1988 and 1989 in Hungary, an epidemiological survey revealed that 58% of all pneumo- coccal isolates and 70% of pneumococcal isolates from children were resistant to penicillin [62]. In most parts of the world where surveillance for resistant pneumococci was performed at several time intervals, appearance of isolates with low to intermediate resistance levels usually preceded the appearance of more highly resistant bacte- ria. During the last decade, the areas with the highest prevalence of penicillin-resistant pneumococci included South Africa, Spain, France, eastern Europe, Israel, South Korea, Japan, New Guinea and the most southerly areas of South America [63, 64]. In the United States, the figure changed abruptly with the proportion of penicillin-resistant strains increasing to about 25% in certain geographic locations [63, 65–68]. In some countries, like in Iceland, penicillin- and multiply antibiotic-resistance emerged in the 1990s, rapidly reaching frequencies close to 20% in S. pneumoniae isolated from children [69]. Recent sur- veillance studies in Latin America, eastern Europe and the United States demonstrated evidence for similar importa- tion of two distinct multiply antibiotic-resistant clones of S. pneumoniae [70–72]. Although the mechanisms of resis- tance are not directly linked, strains resistant to penicillin are much more likely to be resistant to macrolides, tetra- cycline, chloramphenicol and trimethoprim-sulfa- methoxazole [59]. 3.2. Fluoroquinolones A surveillance study performed in Canada in 1988 and between 1993 and 1998 on 7 551 isolates of S. pneumo- niae revealed that reduced susceptibility to fluoroquino- lones increased from 0% in 1993 to 1.7% in 1997 and 1998 and was associated with penicillin resistance [73]. In Spain, among 2 822 pneumococcal strains isolated from 1991 to 1998, 2% were resistant to ciprofloxacin (MIC ≥ 4 µg/mL) with an increase from 0.9% in 1991–1992 to 3% in 1997–1998. A relation was observed between ciprofloxacin resistance and penicillin resistance but also with MLS resistance [74]. Of 1 037 clinical isolates exam- ined from the United Kingdom, 273 showed reduced susceptibility to norfloxacin or ciprofloxacin [28]. From a recent study on 8 419 worldwide clinical isolates of S. pneumoniae obtained during 1997–1998, 69 isolates showed reduced susceptibility or resistance to fluoroqui- nolones [23]. Recently, in Hong Kong, among 181 clinical isolates of S. pneumoniae, 12.1% were found resistant to ciprofloxacin (MIC > 2 µg/mL) [75]. 3.3. MLS Macrolide resistance has been frequently observed, significantly limiting the usefulness of this class of drugs in the treatment of pneumonia. S. pneumoniae resistant to erythromycin was first observed in 1967 in Toronto [18]. In 1992 in France 27.5% of the pneumococcal strains studied were resistant to erythromycin. Between 1991 and 1992 in the United States 3.7 and 2.2% of pneumococcal Review Charpentier and Tuomanen 1858 Microbes and Infection 2000, 1855-0
  • 5. strains isolated in children aged 1–2 years and 3–4 years, respectively, were resistant to erythromycin [76]. Impor- tantly, penicillin-resistant strains are frequently cross- resistant to macrolides [77]. Since the first observation of M resistance in pneumococci in Houston, Texas, the M phenotype was shown to be present in as many as 85% of erythromycin-resistant isolates in the United States [78] and to be significantly increasing in clinical strains iso- lated in South Africa [18]. In a recent study performed in Taiwan, among 200 clinical isolates of S. pneumoniae obtained from January 1996 to December 1997, a very high rate of 82% were erythromycin resistant and 90% clarithromycin resistant [79]. 3.4. Tetracycline Wide use of tetracyclines has resulted in resistance developing in pneumococcal infections. The first pneu- mococcal isolate resistant to tetracycline was isolated in New South Wales in 1963 from a 10-month-old child with pneumococcal meningitis [80]. Since then, reports on tetracycline-resistant pneumococcal clinical isolates have been described in the literature. As an example, among 91 pneumococcal strains isolated in children in Spain, 72.5% were resistant to tetracycline [81]. 3.5. Chloramphenicol Chloramphenicol resistance in pneumococci was first reported in 1970 in Poland, but since has not become a major problem worldwide [18]. Although in Spain 30–50% of clinical isolates of pneumococci have been reported to be resistant to chloramphenicol, less than 5% of pneumo- cocci isolated from other countries showed resistance [82]. In developing countries, where the antibiotic is still widely used, chloramphenicol resistance may be more common. 3.6. Trimethoprim-sulfamethoxazole The first clinical strain of pneumococcus resistant to trimethoprim-sulfamethoxazole was first isolated in 1972 from a patient with an acute exacerbation of chronic bronchitis [83]. The resistance impact in clinical isolates is high, with the highest rate reported in Spain between 1984 and 1986, where the resistance rate among clinical iso- lates was 67% [81]. More than 90% of co-trimoxazole- resistant pneumococcal strains isolated in South Africa are also resistant to penicillin and chloramphenicol [51]. Such a high co-resistance to penicillin prevents the use of co-trimoxazole for the treatment of penicillin-resistant pneumococcal infections. In a recent study performed in Taiwan, among 200 clinical isolates of S. pneumoniae obtained from January 1996 to December 1997, a very high rate of 87% were trimethoprim-sulfamethoxazole resistant [79]. 4. Mechanisms of antibiotic tolerance and bacterial cell death 4.1. Autolytic enzymes Cell wall hydrolases are required to maintain the pep- tidoglycan during bacterial growth and split the septum during cell separation. The expression of most hydrolases is constitutive throughout the cell cycle, but the enzyme is only active during stationary-phase lysis. To act as auto- lysins, the hydrolases completely deregulate and entirely degrade the cell wall [84]. Autolysis due to activation of autolysins like the major autolysin LytA (an N-acetylmuramoyl-L-alanine-amidase) is characteristic for pneumococci. In current models, the antibacterial effects of β-lactam antibiotics are initiated by the binding of antibiotic to PBPs. This binding inhibits specific steps in cell wall synthesis, leading to the cessation of bacterial growth. The bacteria then actively cooperate using their own enzy- matic death machinery to achieve the final killing out- come. Although fundamental to the action of penicillins, the mechanism that explains how the inhibition of cell wall synthesis or the binding of penicillins to PBPs acti- vates autolysins remains unknown [85]. A secondary pro- cess arising from the bacteria itself is necessary to trigger these cell wall hydrolases to lead to cell death. Antibiotic tolerance, a phenomenon distinct from anti- biotic resistance, was first described in 1970 in pneumo- cocci [86]. Antibiotic tolerance is best described by the fact that antibiotic-binding to the bacterium becomes dis- connected from the mechanism of killing. Antibiotic- tolerant pneumococcal strains stop growing in the pres- ence of conventional concentrations of antibiotics, but do not go on to rapidly die. In most cases, antibiotic tolerance goes with reduced lysis of the bacteria. Nevertheless, in some instances, bacteria do not lyse upon binding to a bactericidal antibiotic, but still undergo considerable cell death [87]. Tolerance occurs due to two different settings: phenotypic tolerance and genotypic tolerance. 4.2. Phenotypic tolerance In response to deprivation of an essential nutrient, all bacteria develop resistance to lysis by most β-lactam antibiotics, a phenomenon termed phenotypic tolerance. During this specific metabolic process, called the stringent response, the bacterium shuts down the synthesis of mac- romolecules such as DNA, phospholipids and cell wall peptidoglycan [88]. One major characteristic of pheno- typic tolerance had already been noted in the early 1940s, where it became evident that non-growing bacteria are not killed by penicillin. Since β-lactams bind normally to PBPs of non-growing bacteria, the protection from the bacteri- cidal antibiotic must arise by the control of activity of autolytic enzymes, a process that is poorly understood. This hypothesis is further substantiated by the fact that autolysin preparations from non-growing strains retain their hydrolytic activities when transferred to growing cells. Phenotypic tolerance is not only restricted to depri- vation of essential nutrients, non-growing or slow-growing bacteria. It can also be induced by changes of the bacterial environment, e.g., by lowering the pH of the medium or by adding proteolytic enzymes or inhibitors of the autolytic enzymes [89]. Similarly, addition of lipoteichoic acid (Forssman antigen) to the growth medium of pneumococ- cal cultures causes resistance to stationary-phase lysis and penicillin tolerance, suggesting that lipoteichoic acids might be involved in the in vivo control of autolysin Antibiotic resistance and tolerance in S. pneumoniae Review Microbes and Infection 2000, 1855-0 1859
  • 6. activity. This assumption is supported by the observation that lipoteichoic acids appeared to inhibit autolysin activ- ity in several bacterial species [90–92]. 4.3. Genotypic tolerance In contrast to phenotypic tolerance (a response of all bacteria to environmental changes), tolerance to antibiot- ics can result from genetic mutations. Tolerance arises if either the pneumococcal autolysin, which lyses the cell wall, is not triggered or the autolysin itself is not active or present. The most obvious example of tolerance is the loss-of-function pneumococcal mutant in the autolysin gene, lytA, which fails to lyse and dies very slowly [86]. However, no clinical isolates have been identified harbor- ing a loss-of-function mutation of the autolysin gene. Some studies suggest that 30% of clinical isolates of pneu- mococci are genetically tolerant to penicillin [93]. There- fore, clinical tolerance appears to arise by genetic alter- ation at the level of regulation of autolysin activity [94]. In recent studies, loss-of-function pneumococcal mutants were identified from a library of penicillin-tolerant mutants. Analysis of the strains revealed several different mechanisms interfering with the control of the pneumo- coccal autolytic machinery: a two-component regulatory system (VncS-R), ABC transporters (Psa and Pst), a zinc- metalloprotease (ZmpB) and a heat-shock protein (ClpC) [95–99]. 4.4. Model for the control of bacterial cell death One of the pneumococcal mutants from the library failed to die in the presence of β-lactam antibiotics, includ- ing vancomycin. The affected gene encoded a histidine kinase, VncS, belonging to a two-component regulatory system, VncS–VncR (figure 1) [97]. It was suggested that the two-component system, VncS–VncR, represents an early element in the autolytic trigger pathway, controlling the activity of autolysin via levels of phosphorylation of the response regulator VncR [97]. This implies that VncS– VncR functions as a relay station reacting to cell density signals (stationary-phase lysis) or the binding of antibiotics to PBPs. Although there is still no evident link between cell wall inhibition or PBPs and this system, a signal peptide Pep27 has been identified, which might be a quorum- sensing signal sensed by the two-component system, VncS–VncR, necessary to trigger autolytic activity (figure 1) [100]. 5. Conclusions and perspectives The incidence of penicillin-resistant pneumococci has increased dramatically worldwide, especially in the 1990s. The spread of penicillin resistance appears to be due to a global dissemination of several clones carrying both altered PBP genes and genes encoding resistance to other antibi- otic classes, including macrolides, tetracycline, chloram- phenicol and trimethoprim-sulfamethoxazole. This situa- tion is worsened by the recent emergence of high-level resistance to extended-spectrum third generation cepha- losporins [101]. The last-resort antibiotic for the treatment of multidrug-resistant pneumococcal infections has Figure 1. Model of autolysin triggering. Environmental signals regulate the addition of a phosphoryl group (P) to the sensor kinase (VncS). This, in turn, controls whether the response regulator (VncR) is on (phosphorylated) or off (dephosphorylated). When VncR is phosphorylated, genes that are turned on in response to antibiotics or stationary phase (and induce activation of autolysin, killing the bacteria) are switched off. One of the trigger signals for bacterial lysis seems to be the peptide Pep27 , which acts in a quorum-sensing manner. It is sensed by the two-component system, VncS–VncR, and determines with that the dephosphorylation of VncR, leading to cell death. It remains to be established how and where inhibition of cell wall synthesis by antibiotics feeds into the death peptide pathway. Review Charpentier and Tuomanen 1860 Microbes and Infection 2000, 1855-0
  • 7. become the glycopeptide vancomycin [102]. The rapid emergence of enterococcal strains harboring the vancomycin-resistance gene complex in a highly transfer- able form raises great concern of a likely transfer of van- comycin resistance to multidrug-resistant pneumococci. In addition to a more restricted application of antibiotics, there is an urgent need for new antimicrobial agents that are able to overcome the developed antibiotic-resistance mechanisms. S. pneumoniae is an autolytic pathogen, which regu- lates its suicidal enzymatic system. The downregulation of autolysis leads to tolerance and is of clinical significance as underscored by reports that failure to eradicate tolerant bacteria might result in prolongation and even failure of therapy. Whether this has a broader impact on the general clinical situation still has to be determined, but it seems that in body sites of poor defense like the cerebrospinal fluid compartment, antibiotic-tolerant bacteria might be responsible for relapsing infections and treatment failures [103, 104]. A signal transduction pathway involved in controlling pneumococcal killing was recently uncov- ered. Understanding of the function and regulation of all bacterial suicidal participants is critical for the develop- ment of new antibacterial agents which will not fail in situations of difficult growth conditions. References [1] Hansman D., Glasgow H., Sturt J., Devitt L., Douglas R., Increased resistance to penicillin of pneumococci isolated from man, N. Engl. J. Med. 284 (1971) 175–177. [2] Klugman K.P., Koornhof H.J., Drug resistance patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fluid or blood, 1979–1986, J. Infect. Dis. 158 (1988) 956–964. [3] Goffin C., Ghuysen J.M., Multimodular penicillin- binding proteins: an enigmatic family of orthologs and paralogs, Microbiol. Mol. Biol. Rev. 62 (1998) 1079–1093. [4] Hakenbeck R., Grebe T., Zahner D., Stock J.B., Beta- lactam resistance in Streptococcus pneumoniae: penicillin- binding proteins and non-penicillin-binding proteins, Mol. Microbiol. 33 (1999) 673–678. [5] Hakenbeck R., Mosaic genes and their role in penicillin- resistant Streptococcus pneumoniae, Electrophoresis 19 (1998) 597–601. [6] Grebe T., Hakenbeck R., Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiot- ics, Antimicrob. Agents Chemother. 40 (1996) 829–834. [7] Coffey T.J., Daniels M., McDougal L.K., Dowson C.G., Tenover F.C., Spratt B.G., Genetic analysis of clinical isolates of Streptococcus pneumoniae with high-level resis- tance to expanded-spectrum cephalosporins, Antimicrob. Agents Chemother. 39 (1995) 1306–1313. [8] Laible G., Spratt B.G., Hakenbeck R., Interspecies recom- binational events during the evolution of altered PBP 2x genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae, Mol. Microbiol. 5 (1991) 1993–2002. [9] Garcia-Bustos J., Tomasz A., A biological price of antibi- otic resistance: major changes in the peptidoglycan struc- tureofpenicillin-resistantpneumococci,Proc.Natl.Acad. Sci. USA 87 (1990) 5415–5419. [10] Coffey T.J., Dowson C.G., Daniels M., Spratt B.G., Hori- zontal spread of an altered penicillin-binding protein 2B gene between Streptococcus pneumoniae and Streptococcus ora- lis, FEMS Microbiol. Lett. 110 (1993) 335–339. [11] Hakenbeck R., Konig A., Kern I., van der Linden M., Keck W., Billot-Klein D., Legrand R., Schoot B., Gut- mann L., Acquisition of five high-Mr penicillin-binding protein variants during transfer of high-level beta-lactam resistance from Streptococcus mitis to Streptococcus pneumoniae, J. Bacteriol. 180 (1998) 1831–1840. [12] Chambers H.F., Penicillin-binding protein-mediated resistance in pneumococci and staphylococci, J. Infect. Dis. 179 suppl. 2 (1999) S353–S359. [13] Tomasz A., New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae, Am. J. Med. 107 (1999) 55S–62S. [14] Tomasz A., Antibiotic resistance in Streptococcus pneumo- niae, Clin. Infect. Dis. 24 suppl. 1 (1997) S85–S88. [15] Grebe T., Paik J., Hakenbeck R., A novel resistance mechanism against beta-lactams in Streptococcus pneumoniae involves CpoA, a putative glycosyltransferase, J. Bacteriol. 179 (1997) 3342–3349. [16] Guenzi E., Gasc A.M., Sicard M.A., Hakenbeck R., A two-component signal-transducing system is involved in competence and penicillin susceptibility in laboratory mutants of Streptococcus pneumoniae, Mol. Microbiol. 12 (1994) 505–515. [17] Zechiedrich E.L., Cozzarelli N.R., Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli, Genes Dev. 9 (1995) 2859–2869. [18] Widdowson C.A., Klugman K.P., Molecular mechanisms of resistance to commonly used non-betalactam drugs in Streptococcus pneumoniae, Semin. Respir. Infect. 14 (1999) 255–268. [19] Piddock L.J., Mechanisms of fluoroquinolone resistance: an update 1994–1998, Drugs 58 suppl. 2 (1999) 11–18. [20] Janoir C., Zeller V., Kitzis M.D., Moreau N.J., Gut- mann L., High-level fluoroquinolone resistance in Strepto- coccus pneumoniae requires mutations in parC and gyrA, Antimicrob. Agents Chemother. 40 (1996) 2760–2764. [21] Tankovic J., Perichon B., Duval J., Courvalin P., Contri- bution of mutations in gyrA and parC genes to fluoroqui- nolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro, Antimicrob. Agents Chemother. 40 (1996) 2505–2510. [22] delaCampaA.G.,GarciaE.,FenollA.,MunozR.,Molecu- lar bases of three characteristic phenotypes of pneumococ- cus: optochin-sensitivity, coumarin-sensitivity, and quinolone-resistance, Microb. Drug Resist. 3 (1997) 177–193. Antibiotic resistance and tolerance in S. pneumoniae Review Microbes and Infection 2000, 1855-0 1861
  • 8. [23] Jones M.E., Sahm D.F., Martin N., Scheuring S., Heisig P., Thornsberry C., Kohrer K., Schmitz F.J., Preva- lence of gyrA, gyrB, parC and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased suscepti- bilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997–1998 respiratory season, Antimicrob. Agents Chemother. 44 (2000) 462–466. [24] Pan X.S., Fisher L.M., Targeting of DNA gyrase in Strep- tococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones, Antimicrob. Agents Chemother. 41 (1997) 471–474. [25] Pan X.S., Fisher L.M., DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneu- moniae, Antimicrob. Agents Chemother. 42 (1998) 2810–2816. [26] Perichon B., Tankovic J., Courvalin P., Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae, Antimicrob. Agents Chemother. 41 (1997) 1166–1167. [27] Jorgensen J.H., Weigel L.M., Ferraro M.J., Swenson J.M., Tenover F.C., Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci, Antimi- crob. Agents Chemother. 43 (1999) 329–334. [28] Brenwald N.P., Gill M.J., Wise R., Prevalence of a puta- tive efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae, Antimicrob. Agents Chemother. 42 (1998) 2032–2035. [29] Piddock L.J., Johnson M., Ricci V., Hill S.L., Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract, Antimicrob. Agents Chemother. 42 (1998) 2956–2960. [30] Zeller V., Janoir C., Kitzis M.D., Gutmann L., Moreau N.J., Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae, Antimicrob. Agents Chemother. 41 (1997) 1973–1978. [31] Gill M.J., Brenwald N.P., Wise R., Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae, Antimicrob. Agents Chemother. 43 (1999) 187–189. [32] Vazquez D., Monro R.E., Effects of some inhibitors of protein synthesis on the binding of aminoacyl tRNA to ribosomal subunits, Biochim. Biophys. Acta 142 (1967) 155–173. [33] Weisblum B., Inducible resistance to macrolides, lincosa- mides and streptogramin type B antibiotics: the resistance phenotype, its biological diversity, and structural ele- ments that regulate expression – a review, J. Antimicrob. Chemother. 16 suppl. A (1985) 63–90. [34] Lai C.J., Weisblum B., Altered methylation of ribosomal RNA in an erythromycin-resistant strain of Staphylococcus aureus, Proc. Natl. Acad. Sci. USA 68 (1971) 856–860. [35] Courvalin P., Carlier C., Tn1545: a conjugative shuttle transposon, Mol. Gen. Genet. 206 (1987) 259–264. [36] Tait-Kamradt A., Clancy J., Cronan M., Dib-Hajj F., Wondrack L., Yuan W., Sutcliffe J., mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae, Antimicrob. Agents Chemother. 41 (1997) 2251–2255. [37] Shortridge V.D., Doern G.V., Brueggemann A.B., Beyer J.M., Flamm R.K., Prevalence of macrolide resis- tance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study con- ducted in the United States in 1994–1995, Clin. Infect. Dis. 29 (1999) 1186–1188. [38] Monro R.E., Vazquez D., Ribosome-catalysed peptidyl transfer: effects of some inhibitors of protein synthesis, J. Mol. Biol. 28 (1967) 161–165. [39] Dang-Van A., Tiraby G., Acar J.F., Shaw W.V., Bouan- chaud D.H., Chloramphenicol resistance in Streptococcus pneumoniae: enzymatic acetylation and possible plasmid linkage, Antimicrob. Agents Chemother. 13 (1978) 577–583. [40] Ayoubi P., Kilic A.O., Vijayakumar M.N., Tn5253, the pneumococcal omega (cat tet) BM6001 element, is a com- posite structure of two conjugative transposons, Tn5251 and Tn5252, J. Bacteriol. 173 (1991) 1617–1622. [41] David F., de Cespedes G., Delbos F., Horaud T., Diversity of chromosomal genetic elements and gene identification in antibiotic-resistant strains of Streptococcus pneumoniae and Streptococcus bovis, Plasmid 29 (1993) 147–153. [42] Widdowson C.A., Adrian P.V., Klugman K.P., Acquisi- tion of chloramphenicol resistance by the linearization and integration of the entire staphylococcal plasmid pC194 into the chromosome of Streptococcus pneumoniae, Antimi- crob. Agents Chemother. 44 (2000) 393–395. [43] Burdett V., Inamine J., Rajagopalan S., Heterogeneity of tetracycline resistance determinants in Streptococcus, J. Bac- teriol. 149 (1982) 995–1004. [44] Widdowson C.A., Klugman K.P., Hanslo D., Identifica- tion of the tetracycline resistance gene, tet(O), in Strepto- coccus pneumoniae, Antimicrob. Agents Chemother. 40 (1996) 2891–2893. [45] Martin P., Trieu-Cuot P., Courvalin P., Nucleotide sequence of the tetM tetracycline resistance determinant of the streptococcal conjugative shuttle transposon Tn1545, Nucleic Acids Res. 14 (1986) 7047–7058. [46] Dantley K.A., Dannelly H.K., Burdett V., Binding inter- action between Tet(M) and the ribosome: requirements for binding, J. Bacteriol. 180 (1998) 4089–4092. [47] Manavathu E.K., Fernandez C.L., Cooperman B.S., Tay- lor D.E., Molecular studies on the mechanism of tetracy- cline resistance mediated by Tet(O), Antimicrob. Agents Chemother. 34 (1990) 71–77. [48] Burdett V., tRNA modification activity is necessary for Tet(M)-mediated tetracycline resistance, J. Bacteriol. 175 (1993) 7209–7215. [49] Maskell J.P., Sefton A.M., Hall L.M., Mechanism of sul- fonamide resistance in clinical isolates of Streptococcus pneu- moniae, Antimicrob. Agents Chemother. 41 (1997) 2121–2126. [50] Hitchings G.H., Mechanism of action of trimethoprim- sulfamethoxazole. I, J. Infect. Dis. 128 suppl. (1973) 433–436. [51] Adrian P.V., Klugman K.P., Mutations in the dihydro- folate reductase gene of trimethoprim-resistant isolates of Streptococcus pneumoniae, Antimicrob. Agents Chemother. 41 (1997) 2406–2413. Review Charpentier and Tuomanen 1862 Microbes and Infection 2000, 1855-0
  • 9. [52] Lopez P., Espinosa M., Greenberg B., Lacks S.A., Sulfona- mide resistance in Streptococcus pneumoniae: DNA sequence of the gene encoding dihydropteroate synthase and char- acterization of the enzyme, J. Bacteriol. 169 (1987) 4320–4326. [53] Padayachee T., Klugman K.P., Novel expansions of the gene encoding dihydropteroate synthase in trimethoprim- sulfamethoxazole-resistant Streptococcus pneumoniae, Anti- microb. Agents Chemother. 43 (1999) 2225–2230. [54] Reynolds P.E., Structure, biochemistry and mechanism of action of glycopeptide antibiotics, Eur. J. Clin. Microbiol. Infect. Dis. 8 (1989) 943–950. [55] Arthur M., Reynolds P.E., Courvalin P., Glycopeptide resistance in enterococci, Trends Microbiol. 4 (1996) 401–407. [56] Finland M., Increased resistance in the pneumococcus, N. Engl. J. Med. 284 (1971) 212–214. [57] Appelbaum P.C., Bhamjee A., Scragg J.N., Hallett A.F., Bowen A.J., Cooper R.C., Streptococcus pneumoniae resistant to penicillin and chloramphenicol, Lancet 2 (1977) 995–997. [58] Jacobs M.R., Koornhof H.J., Robins-Browne R.M., Stevenson C.M., Vermaak Z.A., Freiman I., Miller G.B., Witcomb M.A., Isaacson M., Ward J.I., Austrian R., Emergence of multiply resistant pneumococci, N. Engl. J. Med. 299 (1978) 735–740. [59] Forward K.R., The epidemiology of penicillin resistance in Streptococcus pneumoniae, Semin. Respir. Infect. 14 (1999) 243–254. [60] Jorgensen J.H., Doern G.V., Maher L.A., Howell A.W., Redding J.S., Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States, Antimicrob. Agents Chemother. 34 (1990) 2075–2080. [61] Spika J.S., Facklam R.R., Plikaytis B.D., Oxtoby M.J., Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979–1987 The Pneumococcal Surveil- lance Working Group, J. Infect. Dis. 163 (1991) 1273–1278. [62] Marton A., Pneumococcal antimicrobial resistance: the problem in Hungary, Clin. Infect. Dis. 15 (1992) 106–111. [63] Appelbaum P.C., Antimicrobial resistance in Streptococcus pneumoniae: an overview, Clin. Infect. Dis. 15 (1992) 77–83. [64] Baquero F., Pneumococcal resistance to beta-lactam anti- biotics:aglobalgeographicoverview,Microb.DrugResist. 1 (1995) 115–120. [65] Mason E.O. Jr, Kaplan S.L., Lamberth L.B., Tillman J., Increased rate of isolation of penicillin-resistant Streptococ- cus pneumoniae in a children’s hospital and in vitro suscep- tibilities to antibiotics of potential therapeutic use, Anti- microb. Agents Chemother. 36 (1992) 1703–1707. [66] Hofmann J., Cetron M.S., Farley M.M., Baughman W.S., Facklam R.R., Elliott J.A., Deaver K.A., Breiman R.F., The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta, N. Engl. J. Med. 333 (1995) 481–486. [67] Doern G.V., Brueggemann A., Holley H.P. Jr, Rauch A.M., Antimicrobial resistance of Streptococcus pneu- moniae recovered from outpatients in the United States during the winter months of 1994 to1995: results of a 30-center national surveillance study, Antimicrob. Agents Chemother. 40 (1996) 1208–1213. [68] McLinn S., Williams D., Incidence of antibiotic-resistant Streptococcus pneumoniae and beta-lactamase-positive Hae- mophilus influenzae in clinical isolates from patients with otitis media, Pediatr. Infect. Dis. J. 15 (1996) S3–S9. [69] Kristinsson K.G., Hjalmarsdottir M.A., Steingrims- son O., Increasing penicillin resistance in pneumococci in Iceland, Lancet 339 (1992) 1606–1607. [70] Corso A., Severina E.P., Petruk V.F., Mauriz Y.R., Tomasz A., Molecular characterization of penicillin- resistant Streptococcus pneumoniae isolates causing respira- tory disease in the United States, Microb. Drug Resist. 4 (1998) 325–337. [71] Tomasz A., Corso A., Severina E.P., Echaniz-Aviles G., Brandileone M.C., Camou T., Castaneda E., Figueroa O., Rossi A., Di Fabio J.L., Molecular epidemiologic charac- terization of penicillin-resistant Streptococcus pneumoniae invasive pediatric isolates recovered in six Latin-American countries: an overview. PAHO/Rockefeller University Workshop. Pan American Health Organization, Microb. Drug Resist. 4 (1998) 195–207. [72] Setchanova L., Tomasz A., Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates from Bulgaria, J. Clin. Microbiol. 37 (1999) 638–648. [73] Chen D.K., McGeer A., de Azavedo J.C., Low D.E., Decreased susceptibility of Streptococcus pneumoniae to fluo- roquinolones in Canada. Canadian Bacterial Surveillance Network, N. Engl. J. Med. 341 (1999) 233–239. [74] Linares J., de la Campa A.G., Pallares E., Fluoroquinolone resistance in Streptococcus pneumoniae, N. Engl. J. Med. 341 (1999) 1546–1547 discussion 1547–1548. [75] Ho P.L., Que T.L., Tsang D.N., Ng T.K., Chow K.H., Seto W.H., Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae inHongKong,Antimicrob.AgentsChemother.43(1999) 1310–1313. [76] Breiman R.F., Butler J.C., Tenover F.C., Elliott J.A., Facklam R.R., Emergence of drug-resistant pneumococcal infections in the United States, JAMA 271 (1994) 1831–1835. [77] Tomasz A., The pneumococcus at the gates, N. Engl. J. Med. 333 (1995) 514–515. [78] Sutcliffe J., Tait-Kamradt A., Wondrack L., Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system, Antimicrob. Agents Chemother. 40 (1996) 1817–1824. [79] Hsueh P.R., Teng L.J., Lee L.N., Yang P.C., Ho S.W., Luh K.T., Extremely high incidence of macrolide and trimethoprim-sulfamethoxazole resistance among clinical isolates of Streptococcus pneumoniae in Taiwan, J. Clin. Micro- biol. 37 (1999) 897–901. [80] Holt R., Evans T.N., Newman R.L., Tetracycline-resistant pneumococci, Lancet 2 (1969) 545. Antibiotic resistance and tolerance in S. pneumoniae Review Microbes and Infection 2000, 1855-0 1863
  • 10. [81] Latorre Otin C., Jumcasa Morros T., Sanfeliu Sala I., Antibiotic susceptibility of Streptococcus pneumoniae isolates from paediatric patients, J. Antimicrob. Chemother. 22 (1988) 659–665. [82] Perez J.L., Linares J., Bosch J., Lopez de Goicoechea M.J., Martin R., Antibiotic resistance of Streptococcus pneumoniae in childhood carriers, J. Antimicrob. Chemother. 19 (1987) 278–280. [83] Howe J.G., Wilson T.S., Co-trimoxazole-resistant pneu- mococci, Lancet 2 (1972) 184–185. [84] Tomasz A., in: Hakenbeck R., Holtje J.L.H. (Eds.), The target of penicillin, Walter de Gruyter, Berlin, 1983, pp. 155–172. [85] Tomasz A., From penicillin-binding proteins to the lysis and death of bacteria: a 1979 view, Rev. Infect. Dis. 1 (1979) 434–467. [86] Tomasz A., Albino A., Zanati E., Multiple antibiotic resistance in a bacterium with suppressed autolytic sys- tem, Nature 227 (1970) 138–140. [87] Moreillon P., Markiewicz Z., Nachman S., Tomasz A., Two bactericidal targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms, Antimicrob. Agents Chemother. 34 (1990) 33–39. [88] Cashel M., Gentry D.R., Hernandez V.J., Vinella D., in: Neidhardt F.C., Curtis R. III, Ingraham J.L., Lin E.C.C., Low K.B., Magasanik B., Reznikoff W.S., Riley M., Schaechter M., Umbarger H.E. (Eds.), Escherichia coli and Salmonella: cellular and molecular biology, Vol. 1, ASM Press, Washington D.C., 1996. [89] Handwerger S., Tomasz A., Antibiotic tolerance among clinical isolates of bacteria, Rev. Infect. Dis. 7 (1985) 368–386. [90] Cleveland R.F., Holtje J.V., Wicken A.J., Tomasz A., Daneo-Moore L., Shockman G.D., Inhibition of bacterial wall lysins by lipoteichoic acids and related compounds, Biochem. Biophys. Res. Commun. 67 (1975) 1128–1135. [91] Tomasz A., Waks S., Mechanism of action of penicillin: triggering of the pneumococcal autolytic enzyme by inhibitors of cell wall synthesis, Proc. Natl. Acad. Sci. USA 72 (1975) 4162–4166. [92] Cleveland R.F., Wicken A.J., Daneo-Moore L., Shock- man G.D., Inhibition of wall autolysis in Streptococcus faecalis by lipoteichoic acid and lipids, J. Bacteriol. 126 (1976) 192–197. [93] Tuomanen E., Durack D.T., Tomasz A., Antibiotic toler- ance among clinical isolates of bacteria, Antimicrob. Agents Chemother. 30 (1986) 521–527. [94] Tuomanen E., Pollack H., Parkinson A., Davidson M., Facklam R., Rich R., Zak O., Microbiological and clinical significance of a new property of defective lysis in clinical strains of pneumococci, J. Infect. Dis. 158 (1988) 36–43. [95] Novak R., Braun J.S., Charpentier E., Tuomanen E., Peni- cillin tolerance genes of Streptococcus pneumoniae: the ABC- type manganese permease complex Psa, Mol. Microbiol. 29 (1998) 1285–1296. [96] Novak R., Cauwels A., Charpentier E., Tuomanen E., Identification of a Streptococcus pneumoniae gene locus encod- ing proteins of an ABC phosphate transporter and a two- component regulatory system, J. Bacteriol. 181 (1999) 1126–1133. [97] Novak R., Henriques B., Charpentier E., Normark S., TuomanenE.,EmergenceofvancomycintoleranceinStrep- tococcus pneumoniae, Nature 399 (1999) 590–593. [98] Charpentier E., Novak R., Tuomanen E., Regulation of growth inhibition at high temperature, autolysis, trans- formation and adherence in Streptococcus pneumoniae by ClpC, Mol. Microbiol. 37 (2000) 717–726. [99] Novak R., Charpentier E., Braun J.S., Park E., Murti S., Tuomanen E., Masure R., Extracellular targeting of choline-binding proteins in Streptococus pneumoniae by a zincmetalloprotease,Mol.Microbiol.36(2000)366–376. [100] Novak R., Charpentier E., Braun J.S., Tuomanen E., Sig- nal transduction by a death signal peptide: uncovering the mechanism of bacterial killing by penicillin, Mol. Cell 5 (2000) 49–57. [101] McDougal L.K., Rasheed J.K., Biddle J.W., Tenover F.C., Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States, Antimicrob. Agents Chemother. 39 (1995) 2282–2288. [102] Viladrich P.F., Gudiol F., Linares J., Rufi G., Ariza J., Pallares R., Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci, Am. J. Med. 84 (1988) 839–846. [103] McCullers J.A., English B.K., Novak R., Isolation and characterization of vancomycin-tolerant Streptococcus pneu- moniae from the cerebrospinal fluid of a patient who devel- oped recrudescent meningitis, J. Infect. Dis. 181 (2000) 369–373. [104] Zaoutis T., Schneider B., Steele Moore L., Klein J.D., Antibiotic susceptibilities of group C and group G strep- tococci isolated from patients with invasive infections: evidence of vancomycin tolerance among group G sero- types, J. Clin. Microbiol. 37 (1999) 3380–3383. Review Charpentier and Tuomanen 1864 Microbes and Infection 2000, 1855-1864